Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

Abbott And AstraZeneca Submit New Drug Application To The FDA For CERTRIAD(TM), An Investigational Treatment For Mixed Dyslipidemia
Abbott (NYSE: ABT) and AstraZeneca announced that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL- cholesterol (the "bad" cholesterol), high triglycerides and low HDL-cholesterol (the "good" cholesterol). The NDA submission for this investigational compound, containing the active ingredients of CRESTOR(R) (rosuvastatin calcium) and TRILIPIX(R) (fenofibric acid), is supported by data from multiple studies, including efficacy and safety studies with the 5mg, 10mg and 20mg doses of rosuvastatin combined with fenofibric acid. Pending approval of the NDA, the treatment will be marketed as CERTRIAD(TM).
generic viagra online
Is It Time To Consider A Role For MRI Before Prostate Biopsy?
UroToday.com - The prevailing view is that MRI has a limited role in the management of prostate cancer. Currently, the threshold for requesting a pre-treatment staging MRI is variable with most advocating this for only those classified as high risk localized prostate cancer, although some also advocate men with intermediate risk disease.
News of the day
Calixa Therapeutics Announces Initiation Of Phase 2 Clinical Trial Of Its Antibiotic, CXA-101, In Patients With Complicated Urinary Tract Infections
Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo activity against Pseudomonas aeruginosa, including drug resistant isolates. Calixa is investigating CXA-101 as a potential treatment for serious bacterial infections in hospitalized patients.
Sexual Health

Gathering Of Swine Flu Experts At New York Academy Of Sciences May 28

The very latest information on the 2009 swine influenza (H1N1) outbreak is the subject of a landmark afternoon symposium hosted by the New York Academy of Sciences today, Thursday, May 28. Speakers will discuss the new recombinant virus, epidemiology, treatment, vaccine development and the public health implications of a worldwide pandemic. Reservations are required to attend the conference, held from 12:30 p.m. to 5:30 p.m., at academy offices, 7 World Trade Center, 40th floor, 250 Greenwich St. at Barclay St. A reception will follow. Two microbiologists/immunologists from New York Medical College are leading the symposium, which will focus on understanding the pathogenicity and transmission of the viruses to develop improved methods of prevention and control. Keynote speaker Edwin D. Kilbourne, M.D., emeritus professor, developed the first genetically engineered vaccine of any kind more than 30 years ago. He is an internationally recognized research scientist who has made significant contributions to the study and prevention of influenza and other viral diseases. Doris Bucher, Ph.D., associate professor, whose laboratory in Valhalla is one of just three worldwide that reproduces "seed" viruses for the influenza vaccine, which begins the process of producing some 450 million doses of a new vaccine each year. Dr. Bucher is the symposium organizer. Speakers include Michael Shaw, CDC Influenza Division; Dominick A. Iacuzio, Hoffman-La Roche, Inc.; Kanta Subbarao, NIH Laboratory of Infectious Diseases; John Treanor, University of Rochester School of Medicine and Dentistry; Philip R. Dormitzer, Novartis Vaccines; Scott Harper, New York City Department of Health and Mental Hygiene; and James Matthews, Sanofi Pasteur, moderator. Information and directions at http://www.nyas.org/about/directions.asp. The program also will be broadcast as a live Webinar, and is sponsored by Emerging Infectious Diseases and Microbiology Discussion Group of the New York Academy of Sciences. Donna E. Moriarty, M.P.H. New York Medical College


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009